352 related articles for article (PubMed ID: 31585718)
21. KRAS G12V Mutation in Acquired Resistance to Combined BRAF and MEK Inhibition in Papillary Thyroid Cancer.
Owen DH; Konda B; Sipos J; Liu T; Webb A; Ringel MD; Timmers CD; Shah MH
J Natl Compr Canc Netw; 2019 May; 17(5):409-413. PubMed ID: 31085763
[TBL] [Abstract][Full Text] [Related]
22. Pneumatosis intestinalis in a radioactive iodine-refractory metastasic thyroid papillary carcinoma with BRAF
Martín-Soberón MC; Ruiz S; De Velasco G; Yarza R; Carretero A; Castellano D; Sepúlveda-Sánchez JM
J Med Case Rep; 2021 Mar; 15(1):109. PubMed ID: 33653337
[TBL] [Abstract][Full Text] [Related]
23. Targeting
Burkart J; Owen D; Shah MH; Abdel-Misih SRZ; Roychowdhury S; Wesolowski R; Haraldsdottir S; Reeser JW; Samorodnitsky E; Smith A; Konda B
J Natl Compr Canc Netw; 2018 Sep; 16(9):1035-1040. PubMed ID: 30181415
[TBL] [Abstract][Full Text] [Related]
24. NADPH Oxidase NOX4 Is a Critical Mediator of BRAF
Azouzi N; Cailloux J; Cazarin JM; Knauf JA; Cracchiolo J; Al Ghuzlan A; Hartl D; Polak M; Carré A; El Mzibri M; Filali-Maltouf A; Al Bouzidi A; Schlumberger M; Fagin JA; Ameziane-El-Hassani R; Dupuy C
Antioxid Redox Signal; 2017 May; 26(15):864-877. PubMed ID: 27401113
[TBL] [Abstract][Full Text] [Related]
25. The oncogene BRAF V600E is associated with a high risk of recurrence and less differentiated papillary thyroid carcinoma due to the impairment of Na+/I- targeting to the membrane.
Riesco-Eizaguirre G; Gutiérrez-Martínez P; García-Cabezas MA; Nistal M; Santisteban P
Endocr Relat Cancer; 2006 Mar; 13(1):257-69. PubMed ID: 16601293
[TBL] [Abstract][Full Text] [Related]
26. Inverse Agonist of Estrogen-Related Receptor γ Enhances Sodium Iodide Symporter Function Through Mitogen-Activated Protein Kinase Signaling in Anaplastic Thyroid Cancer Cells.
Singh TD; Jeong SY; Lee SW; Ha JH; Lee IK; Kim SH; Kim J; Cho SJ; Ahn BC; Lee J; Jeon YH
J Nucl Med; 2015 Nov; 56(11):1690-6. PubMed ID: 26338896
[TBL] [Abstract][Full Text] [Related]
27. Effects of BRAF(V600E) mutation on Na(+)/I(-) symporter expression in papillary thyroid carcinoma.
Dong H; Shen WZ; Yan YJ; Yi JL; Zhang L
J Huazhong Univ Sci Technolog Med Sci; 2016 Feb; 36(1):77-81. PubMed ID: 26838744
[TBL] [Abstract][Full Text] [Related]
28. Comparison of dabrafenib and trametinib combination therapy with vemurafenib monotherapy on health-related quality of life in patients with unresectable or metastatic cutaneous BRAF Val600-mutation-positive melanoma (COMBI-v): results of a phase 3, open-label, randomised trial.
Grob JJ; Amonkar MM; Karaszewska B; Schachter J; Dummer R; Mackiewicz A; Stroyakovskiy D; Drucis K; Grange F; Chiarion-Sileni V; Rutkowski P; Lichinitser M; Levchenko E; Wolter P; Hauschild A; Long GV; Nathan P; Ribas A; Flaherty K; Sun P; Legos JJ; McDowell DO; Mookerjee B; Schadendorf D; Robert C
Lancet Oncol; 2015 Oct; 16(13):1389-98. PubMed ID: 26433819
[TBL] [Abstract][Full Text] [Related]
29. Aberrant modulation of ribosomal protein S6 phosphorylation confers acquired resistance to MAPK pathway inhibitors in BRAF-mutant melanoma.
Gao MZ; Wang HB; Chen XL; Cao WT; Fu L; Li Y; Quan HT; Xie CY; Lou LG
Acta Pharmacol Sin; 2019 Feb; 40(2):268-278. PubMed ID: 29777202
[TBL] [Abstract][Full Text] [Related]
30. Redifferentiation of a
Leboulleux S; Dupuy C; Lacroix L; Attard M; Grimaldi S; Corre R; Ricard M; Nasr S; Berdelou A; Hadoux J; Hartl D; Terroir M; Baudin E; Schlumberger M; Al Ghuzlan A
Thyroid; 2019 May; 29(5):735-742. PubMed ID: 30880598
[TBL] [Abstract][Full Text] [Related]
31. Triple Therapy Improves Colorectal Cancer Response.
Cancer Discov; 2016 Dec; 6(12):OF6. PubMed ID: 27770002
[TBL] [Abstract][Full Text] [Related]
32. Acquired Secondary RAS Mutation in BRAF
Cabanillas ME; Dadu R; Iyer P; Wanland KB; Busaidy NL; Ying A; Gule-Monroe M; Wang JR; Zafereo M; Hofmann MC
Thyroid; 2020 Sep; 30(9):1288-1296. PubMed ID: 32216548
[No Abstract] [Full Text] [Related]
33. Combined BRAF, EGFR, and MEK Inhibition in Patients with
Corcoran RB; André T; Atreya CE; Schellens JHM; Yoshino T; Bendell JC; Hollebecque A; McRee AJ; Siena S; Middleton G; Muro K; Gordon MS; Tabernero J; Yaeger R; O'Dwyer PJ; Humblet Y; De Vos F; Jung AS; Brase JC; Jaeger S; Bettinger S; Mookerjee B; Rangwala F; Van Cutsem E
Cancer Discov; 2018 Apr; 8(4):428-443. PubMed ID: 29431699
[TBL] [Abstract][Full Text] [Related]
34. BRAF-V600E mutant papillary craniopharyngioma dramatically responds to combination BRAF and MEK inhibitors.
Roque A; Odia Y
CNS Oncol; 2017 Apr; 6(2):95-99. PubMed ID: 28425764
[TBL] [Abstract][Full Text] [Related]
35. Combination of dabrafenib plus trametinib for BRAF and MEK inhibitor pretreated patients with advanced BRAF
Schreuer M; Jansen Y; Planken S; Chevolet I; Seremet T; Kruse V; Neyns B
Lancet Oncol; 2017 Apr; 18(4):464-472. PubMed ID: 28268064
[TBL] [Abstract][Full Text] [Related]
36. Unbiased Proteomic and Phosphoproteomic Analysis Identifies Response Signatures and Novel Susceptibilities After Combined MEK and mTOR Inhibition in BRAF
Maxwell MJ; Arnold A; Sweeney H; Chen L; Lih TM; Schnaubelt M; Eberhart CG; Rubens JA; Zhang H; Clark DJ; Raabe EH
Mol Cell Proteomics; 2021; 20():100123. PubMed ID: 34298159
[TBL] [Abstract][Full Text] [Related]
37. Thyroid stimulating hormone increases iodine uptake by thyroid cancer cells during BRAF silencing.
Kleiman DA; Buitrago D; Crowley MJ; Beninato T; Veach AJ; Zanzonico PB; Jin M; Fahey TJ; Zarnegar R
J Surg Res; 2013 Jun; 182(1):85-93. PubMed ID: 22998776
[TBL] [Abstract][Full Text] [Related]
38. Checkpoint Inhibition in Addition to Dabrafenib/Trametinib for BRAF
Hamidi S; Iyer PC; Dadu R; Gule-Monroe MK; Maniakas A; Zafereo ME; Wang JR; Busaidy NL; Cabanillas ME
Thyroid; 2024 Mar; 34(3):336-346. PubMed ID: 38226606
[No Abstract] [Full Text] [Related]
39. Small-molecule MAPK inhibitors restore radioiodine incorporation in mouse thyroid cancers with conditional BRAF activation.
Chakravarty D; Santos E; Ryder M; Knauf JA; Liao XH; West BL; Bollag G; Kolesnick R; Thin TH; Rosen N; Zanzonico P; Larson SM; Refetoff S; Ghossein R; Fagin JA
J Clin Invest; 2011 Dec; 121(12):4700-11. PubMed ID: 22105174
[TBL] [Abstract][Full Text] [Related]
40. Clinical Development of BRAF plus MEK Inhibitor Combinations.
Subbiah V; Baik C; Kirkwood JM
Trends Cancer; 2020 Sep; 6(9):797-810. PubMed ID: 32540454
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
